• Clinical Insights: September 15, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Aliqopa™ (copanlisib) – September 14, 2017 – The U.S. Food and Drug Administration granted accelerated approval to Aliqopa™ (copanlisib) for the treatment of adults with relapsed… Read more »

  • Temporary Corporate Office Closure Due To Hurricane Irma

    RxStrategies’ corporate office is based in South Florida, and as such, the area is recovering from the impact of Hurricane Irma.  As local authorities work to clear roadways and restore power to the area, RxStrategies’ corporate office will remain closed on Wednesday, September 13. We will continue to keep you updated regarding when the corporate office will be operational.… Read more »

  • Temporary Corporate Office Closure in Advance of Hurricane Irma

    RxStrategies corporate office is based in South Florida, and as such we are preparing to deal with the impacts of Hurricane Irma. In recognition of the potential seriousness of Hurricane Irma, and consistent with local and state governmental authorities’ recommendations, the RxStrategies’ corporate office will be closed Thursday and Friday (September 8 & 9). Depending upon the events of the weekend,… Read more »

  • Clinical Insights: August 25, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Gocovri™ (amantadine) – August 24, 2017 – Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri™ (amantadine) extended release capsules… Read more »

  • Clinical Insights: August 18, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Besponsa® (inotuzumab ozogamicin) – August 17, 2017 – The U.S. Food and Drug Administration approved Besponsa® (inotuzumab ozogamicin) for the treatment of adults with relapsed or… Read more »

  • Clinical Insights: August 11, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval CaroSpir® (spironolactone) – August 7, 2017 – CMP Pharma announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the company’s New… Read more »

  • Join Us at the 2017 NACHC – CHI & EXPO!

    August 25-29, 2017, the RxStrategies team, including, Rhodie Smith (Vice President of Contract Pharmacy Sales), Jon Braff (National Sales Manager – West) and Jordan Hytken (Senior Account Executive), will be connecting with industry leaders at the National Association of Community Health Centers (NACHC) Community Health Institute (CHI) & EXPO in San Diego, California. Get more… Read more »

  • Clinical Insights: August 4, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vyxeos™ (cytarabine and daunorubicin) – August 3, 2017 – The U.S. Food and Drug Administration approved Vyxeos™ for the treatment of adults with two types of acute… Read more »

  • Clinical Insights: July 28, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) – July 18, 2017 – The U.S. Food and Drug Administration approved Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without… Read more »

  • Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »